Holen Sie sich die Stockscreener-App
0.58
2.06%
0.0117
Handel nachbörslich:
.58
Schlusskurs vom Vortag:
$0.5683
Offen:
$0.5744
24-Stunden-Volumen:
364.32K
Relative Volume:
0.76
Marktkapitalisierung:
$21.92M
Einnahmen:
$1.38M
Nettoeinkommen (Verlust:
$-179.05M
KGV:
-0.0816
EPS:
-7.11
Netto-Cashflow:
$-155.03M
1W Leistung:
-19.42%
1M Leistung:
+2.51%
6M Leistung:
-71.98%
1J Leistung:
-85.96%
1-Tages-Spanne:
$0.511
$0.5838
1-Wochen-Bereich:
$0.50
$0.7157
52-Wochen-Spanne:
$0.50
$4.25
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Firmenname
Bioxcel Therapeutics Inc
Sektor
Branche
Telefon
203-643-8060
Adresse
555 LONG WHARF DRIVE, NEW HAVEN, CT
Vergleichen Sie BTAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BTAI | 0.58 | 21.92M | 1.38M | -179.05M | -155.03M | -7.11 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-07-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-03-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-01 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-06 | Bestätigt | BofA Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-30 | Eingeleitet | Goldman | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-04 | Eingeleitet | Guggenheim | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com UK
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan
BioXcel Therapeutics reports executive transition - Investing.com India
BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia
Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily
BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa
BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com Australia
BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia
Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com
BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com
BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com
BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com
BTAI Shares Experience Decline in Value - Knox Daily
Finanzdaten der Bioxcel Therapeutics Inc-Aktie (BTAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):